Cargando…
Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C
Certain hepatitis C virus (HCV) carriers exhibit persistently normal alanine aminotransferase (ALT) levels (PNALT) (≤30 IU/l) accompanied by normal platelet counts (≥15×10(4)/μl); these individuals show milder disease activity and slower progression to cirrhosis. This study aimed to elucidate the ch...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493081/ https://www.ncbi.nlm.nih.gov/pubmed/22614103 http://dx.doi.org/10.3892/mmr.2012.924 |
_version_ | 1782249212562374656 |
---|---|
author | IMAKIIRE, KAZUYUKI UTO, HIROFUMI SATO, YUKO SASAKI, FUMISATO MAWATARI, SEIICHI IDO, AKIO SHIMODA, KAZUYA HAYASHI, KATSUHIRO STUVER, SHERRI O. ITO, YOSHITO OKANOUE, TAKESHI TSUBOUCHI, HIROHITO |
author_facet | IMAKIIRE, KAZUYUKI UTO, HIROFUMI SATO, YUKO SASAKI, FUMISATO MAWATARI, SEIICHI IDO, AKIO SHIMODA, KAZUYA HAYASHI, KATSUHIRO STUVER, SHERRI O. ITO, YOSHITO OKANOUE, TAKESHI TSUBOUCHI, HIROHITO |
author_sort | IMAKIIRE, KAZUYUKI |
collection | PubMed |
description | Certain hepatitis C virus (HCV) carriers exhibit persistently normal alanine aminotransferase (ALT) levels (PNALT) (≤30 IU/l) accompanied by normal platelet counts (≥15×10(4)/μl); these individuals show milder disease activity and slower progression to cirrhosis. This study aimed to elucidate the characteristics of HCV carriers with PNALT using serum proteomics. The first group of subjects, who underwent clinical evaluation in the hospital, consisted of 19 HCV carriers with PNALT (PNALT-1) and 20 chronic hepatitis C (CHC-1) patients. The second group of subjects was part of a cohort study on the natural history of liver disease, and included 37 PNALT (PNALT-2) and 30 CHC (CHC-2) patients. Affinity bead-purified serum protein was subjected to matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis. Serum proteomics showed that 6 protein peaks with mass-to-charge ratios ranging from 1,000 to 3,000 differed significantly between the PNALT-1 and CHC-1 groups. Among these peaks, a 1738-m/z peak protein was identified as a fragment of complement component 4 (C4) and correlated significantly with serum C4a concentrations as determined by enzyme immunoassay. Serum C4a levels were also significantly higher in the PNALT-2 group compared to the CHC-2 group and healthy volunteers. Furthermore, in the PNALT-2 group, serum C4a levels negatively correlated with transaminase levels, but not with other biochemical tests, HCV core antigen levels, peripheral blood cell counts or serum hepatic fibrosis markers. This study indicates that host factors such as C4a not only differ between HCV carriers with PNALT and CHC, but that proteomic approaches could also contribute to the elucidation of factors in PNALT as more differences are discovered. |
format | Online Article Text |
id | pubmed-3493081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-34930812013-02-14 Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C IMAKIIRE, KAZUYUKI UTO, HIROFUMI SATO, YUKO SASAKI, FUMISATO MAWATARI, SEIICHI IDO, AKIO SHIMODA, KAZUYA HAYASHI, KATSUHIRO STUVER, SHERRI O. ITO, YOSHITO OKANOUE, TAKESHI TSUBOUCHI, HIROHITO Mol Med Rep Articles Certain hepatitis C virus (HCV) carriers exhibit persistently normal alanine aminotransferase (ALT) levels (PNALT) (≤30 IU/l) accompanied by normal platelet counts (≥15×10(4)/μl); these individuals show milder disease activity and slower progression to cirrhosis. This study aimed to elucidate the characteristics of HCV carriers with PNALT using serum proteomics. The first group of subjects, who underwent clinical evaluation in the hospital, consisted of 19 HCV carriers with PNALT (PNALT-1) and 20 chronic hepatitis C (CHC-1) patients. The second group of subjects was part of a cohort study on the natural history of liver disease, and included 37 PNALT (PNALT-2) and 30 CHC (CHC-2) patients. Affinity bead-purified serum protein was subjected to matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis. Serum proteomics showed that 6 protein peaks with mass-to-charge ratios ranging from 1,000 to 3,000 differed significantly between the PNALT-1 and CHC-1 groups. Among these peaks, a 1738-m/z peak protein was identified as a fragment of complement component 4 (C4) and correlated significantly with serum C4a concentrations as determined by enzyme immunoassay. Serum C4a levels were also significantly higher in the PNALT-2 group compared to the CHC-2 group and healthy volunteers. Furthermore, in the PNALT-2 group, serum C4a levels negatively correlated with transaminase levels, but not with other biochemical tests, HCV core antigen levels, peripheral blood cell counts or serum hepatic fibrosis markers. This study indicates that host factors such as C4a not only differ between HCV carriers with PNALT and CHC, but that proteomic approaches could also contribute to the elucidation of factors in PNALT as more differences are discovered. D.A. Spandidos 2012-08 2012-05-21 /pmc/articles/PMC3493081/ /pubmed/22614103 http://dx.doi.org/10.3892/mmr.2012.924 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles IMAKIIRE, KAZUYUKI UTO, HIROFUMI SATO, YUKO SASAKI, FUMISATO MAWATARI, SEIICHI IDO, AKIO SHIMODA, KAZUYA HAYASHI, KATSUHIRO STUVER, SHERRI O. ITO, YOSHITO OKANOUE, TAKESHI TSUBOUCHI, HIROHITO Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title | Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title_full | Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title_fullStr | Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title_full_unstemmed | Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title_short | Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C |
title_sort | difference in serum complement component c4a levels between hepatitis c virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis c |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493081/ https://www.ncbi.nlm.nih.gov/pubmed/22614103 http://dx.doi.org/10.3892/mmr.2012.924 |
work_keys_str_mv | AT imakiirekazuyuki differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT utohirofumi differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT satoyuko differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT sasakifumisato differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT mawatariseiichi differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT idoakio differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT shimodakazuya differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT hayashikatsuhiro differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT stuversherrio differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT itoyoshito differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT okanouetakeshi differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc AT tsubouchihirohito differenceinserumcomplementcomponentc4alevelsbetweenhepatitiscviruscarrierswithpersistentlynormalalanineaminotransferaselevelsorchronichepatitisc |